Skip to content
Biogen Pharmachem Industries logo

Biogen Pharmachem Industries

531752 BSE
₹0.25

Close ·

P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 4 Nov 2026 ₹0.25 −0.44 −63.8% 1Y
Start ₹0.69

Key Fundamentals

MicrocapFinanceFinancial Services

Price-based figures at the close · EPS basis: Standalone · TTM

ROCE
1.01%
Debt to Equity
0.00
EPS (TTM)
₹0.00
Book Value
₹0.94
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
0.27
ROE
0.90%
Dividend Yield
0.00%
EBITDA
₹1.00 Cr
52W High
₹0.72
52W Low
₹0.23

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

51 Average

Data confidence 91/100

Category scores

Quality
53
Average
Returns, margins, earnings quality 22% weight
Valuation
67
Strong
Cheap vs sector & own history 24% weight
Growth
55
Average
Sales & profit trajectory 9% weight
Financial Health
73
Strong
Solvency, leverage, coverage 9% weight
Momentum
10
Poor
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Stock is trading at 0.29 times its book value

Weaknesses

2
  • Company has low interest coverage ratio.
  • Company has a low return on equity of 1.11% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1450
OscillatorsBearish450
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
43.34
Neutral
MACD (12,26,9)
−0.01
Bearish
SMA (50)
0.27
Bearish
SMA (200)
0.38
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10YZero base
5Y+9.50%
3YZero base
1Y+112.50%
TTM+15.56%

Net profit

Net profit growth by window
10YTurned to profit
5YTurned to profit
3Y+23.19%
1YTurned to profit
TTMTurned to loss

Operating cash flow

Operating cash flow growth by window
10Y−10.35%
5Y−16.85%
3Y−2.62%
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YNo sales
5Y+136.02 pp
3YNo sales
1Y+61.42 pp
TTM−11.16 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹0.11 Cr
Mar 2019₹0.95 Cr
Mar 2020₹0.00 Cr
Mar 2021₹1.62 Cr
Mar 2022₹2.47 Cr
Mar 2023₹0.00 Cr
Mar 2024₹2.38 Cr
Mar 2025₹1.20 Cr
Mar 2026₹2.55 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017−₹0.12 Cr
Mar 2018−₹6.56 Cr
Mar 2019₹0.00 Cr
Mar 2020−₹0.12 Cr
Mar 2021−₹1.60 Cr
Mar 2022−₹0.01 Cr
Mar 2023₹0.46 Cr
Mar 2024₹1.93 Cr
Mar 2025−₹0.29 Cr
Mar 2026₹0.86 Cr

Quarterly Results

₹ Cr
531752 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0.75
0
0
0.78
−0.09
0
0
1.35
0
0
0.54
0.58
0.44
Expenses
0.34
0.04
0.03
0.04
0.07
0.35
0.54
0.17
0.2
0.39
0.08
0.94
0.22
Operating Profit
0.41
−0.04
−0.03
0.74
−0.16
−0.35
−0.54
1.18
−0.2
−0.39
0.46
−0.36
0.22
OPM %
54.67%
—
—
94.87%
—
—
—
87.41%
—
—
85.19%
−62.07%
50%
Other Income
0
0.76
0.09
0
0
−0.65
0.23
0
1.54
−0.1
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0.41
0.72
0.06
0.74
−0.16
−1
−0.31
1.18
1.34
−0.49
0.46
−0.36
0.22
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
0.41
0.72
0.06
0.74
−0.16
−1
−0.31
1.18
1.34
−0.49
0.46
−0.36
0.22
EPS (₹)
0.01
0.01
0
0.01
0
−0.01
0
0.02
0.01
0
0
0
0

Profit & Loss

₹ Cr
531752 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
0
0
0.11
0.95
0
1.62
2.47
0
2.38
1.2
2.55
1.56
Expenses
0.04
0.03
0.12
6.72
0.95
0.12
3.22
2.49
0.45
0.45
1.49
1.6
1.63
Operating Profit
−0.04
−0.03
−0.12
−6.61
0
−0.12
−1.6
−0.02
−0.45
1.93
−0.29
0.95
−0.07
OPM %
—
—
—
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
0%
—
−98.77%
−0.81%
—
81.09%
−24.17%
37.25%
−4.49%
Other Income
0
0
0
0.05
0
0
0
0.01
0.91
0
0
0.01
−0.1
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0.1
0
0
0
0
0
0
0
0
0
0
0
0
PBT
−0.14
−0.03
−0.12
−6.56
0
−0.12
−1.6
−0.01
0.46
1.93
−0.29
0.96
−0.17
Tax %
0%
0%
0%
0%
—
0%
0%
0%
0%
0%
0%
10.42%
—
Net Profit
−0.13
−0.03
−0.12
−6.56
0
−0.12
−1.6
−0.01
0.46
1.93
−0.29
0.86
−0.17
EPS (₹)
0
0
0
−0.09
0
0
−0.02
0
0.01
0.03
0
0.01
0
Div. Payout %
0%
0%
0%
0%
—
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
531752 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
65.26
65.26
65.26
65.26
65.26
65.26
65.26
65.26
65.26
65.26
65.26
90.26
Reserves
−4.27
−4.3
−4.42
−10.98
−10.99
−9.51
−11.12
−11.13
−10.67
−8.74
26.67
8.83
Borrowings
10
6.21
0.72
0.01
0.63
0.31
0
0
0
0
0
0
Other Liabilities
2.49
1.64
1.69
1.64
2.73
0.03
0.11
0.82
0.24
0.3
0.09
0.31
Total Liabilities
73.48
68.81
63.25
55.93
57.63
56.09
54.25
54.95
54.83
56.82
92.02
99.4
Fixed Assets
0
0
0
0
0
0
0
0
0
0
0
0
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
43.78
26.69
22.39
3.52
6.25
6.45
9.49
6.95
8.85
5.44
23.84
32.78
Other Assets
29.7
42.12
40.86
52.41
51.38
49.64
44.76
48
45.98
51.38
68.18
66.62
Total Assets
73.48
68.81
63.25
55.93
57.63
56.09
54.25
54.95
54.83
56.82
92.02
99.4

Cash Flow

₹ Cr
531752 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−7.28
4.68
−0.07
−13.65
0.09
−1.21
3.95
1.4
1.7
1.94
−1.08
1.57
Investing
17.08
17.08
4.3
14.32
−0.72
1.54
−3.64
−1.32
−1.66
−2.06
−32.62
−9.56
Financing
−11.19
−21.74
−4.31
−0.71
0.62
−0.32
−0.31
0
0
0
35.7
6.3
Net Cash Flow
−1.38
0.02
−0.07
−0.03
−0.02
0
0
0.08
0.05
−0.11
2
−1.69
Free Cash Flow
−7.28
4.68
−0.07
−13.65
0.09
−1.21
3.95
1.4
1.7
1.94
−1.08
1.57
CFO/OP
18,200
−15,600
58
207
—
1,008
−247
−7,000
−378
101
372
176

Ratios

531752 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
—
—
—
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
3,085
—
572
0
—
0
0
0
Inventory Days
—
—
—
—
0
—
0
0
—
—
—
—
Cash Conversion Cycle
—
—
—
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
3,085
—
572
0
—
0
0
0
Working Capital Days
—
—
—
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
2,651
—
550
152
—
−35.27
170
−20.04
ROCE %
−0.15%
−0.04%
−0.19%
−11.32%
0%
−0.22%
−2.9%
−0.02%
−0.37%
3.47%
−0.39%
1.01%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Biogen Pharmachem Industries insights

56 extracted metrics across FY09–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 77.27%
  • Others 22.73%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Biogen Pharmachem Industries

What does Biogen Pharmachem Industries Ltd do?
Incorporated in 1995, Biogen Pharmachem Industries Ltd is in the business of trading in shares and securities.
Where is Biogen Pharmachem Industries Ltd (BIOGEN) listed?
Biogen Pharmachem Industries Ltd trades under code 531752 on the BSE.
Which sector does Biogen Pharmachem Industries Ltd belong to?
Biogen Pharmachem Industries Ltd is classified under the Financial Services sector, in the Other Financial Services industry.
What is the 52-week high and low of Biogen Pharmachem Industries Ltd?
Over the last 52 weeks Biogen Pharmachem Industries Ltd has traded between ₹0.23 and ₹0.72 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Biogen Pharmachem Industries Ltd?
Biogen Pharmachem Industries Ltd reported a return on equity of 0.90%. Its debt-to-equity ratio is 0.00.

Company Information

Incorporated in 1995, Biogen Pharmachem Industries Ltd is in the business of trading in shares and securities.

Website suntechnooverseas.in
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531752.md for Biogen Pharmachem Industries Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More NBFC & Finance stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month